Piper Jaffray Upgrades Hologic (HOLX) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Evercore ISI Downgrades Hologic (HOLX) to Hold
January 4, 2017 6:17 AM ESTEvercore ISI downgraded Hologic (NASDAQ: HOLX) from Buy to Hold with a price target of $42.00 citing mixed EPS trajectory in the near term.
Analyst Vijay Kumar commented, "'Beauty lies in the eye of the beholder' is certainly true for investing, where a... More
Hologic (HOLX) Granted FDA PMA Approval for HIV-1 Viral Load Monitoring Assay Aptima
January 3, 2017 8:12 AM ESTHologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has granted PMA approval for the Company's HIV-1 viral load monitoring assay. The Aptima® HIV-1 Quant assay is a nucleic acid amplification test for the quantitative detection of RNA from HIV in plasma specimens.
The Aptima HIV-1 Quant assay runs on Hologic's Panther® system, a market-leading, integrated platform that fully automates all aspects of testing, from sample to result. The system substantially reduces hands-on time for laboratories by providing random and continuous access with rapid turnaround... More
